The wait is finally over for Myriad Genetics, Inc MYGN. The company recently received favorable Medicare local coverage determination (LCD) for its Prolaris diagnostic test, which is used to evaluate the aggressiveness of prostate cancer in patients. Noridian – the local Medicare Administrative Contractor (MAC) that processes all Medicare claims from Myriad – issued the final LCD.
Join the club! I'm not even returning my brokers calls anymore. Got a margin call last week at $54 and covered, however now I'm completely tapped out....so let the pieces fall where thay may. Armegeddon is here my friends..IT'S OVER!!